Deactivation of endocannabinoids in the brain helps treat depression
Pippa Murdie
This article has no abstract so we have provided the first paragraph of the full text.
A trial of URB597 in mice and rats has shown this fatty-acid amide hydrolase inhibitor to be an effective mood regulator with potential for treating depression. The drug, which interferes with deactivation of the endogenous cannabinoid anandamide in the brain, produces similar mood-enhancing effects to cannabis, but is not associated with psychotropic effects or addiction.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Neurobiology Cannabinoids act backwardsNature News and Views (29 Mar 2001)
TREKing toward new antidepressantsNature Neuroscience News and Views (01 Sep 2006)